Vivus rises on plumpness drug capitulation for Arena

<p>NEW YORK (AP) — Shares of <span>Vivus Inc.</span> climbed Wednesday after regulators authorized a opposition <span>obesity drug</span>, lifting hopes that Vivus’ drug Qnexa will be privileged in July.</p>
<p>THE SPARK: The <span>Food and Drug Administration</span> authorized <span>Arena Pharmaceuticals Inc.</span>‘s drug Belviq Wednesday. Belviq will be a initial new <span>prescription drug</span> for long-term weight detriment to enter a U.S. marketplace in over a decade. The FDA is scheduled to make a preference on Qnexa by Jul 17.</p>
<p>THE BIG PICTURE: Vivus, Arena, and <span>Orexigen Therapeutics Inc.</span> have all sought selling capitulation for anti-obesity drugs in a final few years. The FDA refused to approve one drug from any association in 2010 and 2011 since of concerns about their reserve and effectiveness. The companies conducted serve contrast to support their prod...